STAT+: Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup
Good morning! Elizabeth Cooney here, sitting in for Ed Silverman, who would no doubt be…
Category: STAT+
STAT+: Peter Bach, industry critic, joins company aiming to make blood tests to detect cancer
Peter Bach, well-known as a drug pricing researcher and pharma industry gadfly, is leaving academia…
STAT+: Teva to pay $925,000 to Mississippi to settle generic price-fixing charges
After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of…
STAT+: Key science officials detail their plans for a new research agency — and Congress is getting closer to funding it
WASHINGTON — Two key federal health officials are pitching a new branch of the National…
STAT+: Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs
WASHINGTON — Sen. Ron Wyden (D-Ore.), the influential chair of the Senate Finance Committee, is…
STAT+: Pharmalittle: Biogen isn’t the only company to make big bucks from its Alzheimer’s drug; EU extends Covid-19 vax export block
Hello, everyone, and how are you this morning? Some puffy clouds are hovering over the…
STAT+: Pear Therapeutics to go public in $1.6 billion SPAC merger
Barreling forward with its early momentum in the digital therapeutics market, Pear Therapeutics announced Tuesday…
STAT+: Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm
WASHINGTON — Biogen’s expecting to make billions from its newly approved Alzheimer’s drug Aduhelm. But…
STAT+: ‘It’s hard to know what’s trustworthy’: A new research effort aims to vet digital health data from wearables
Covid-19 upended the way clinical trials get done — and don’t get done. With in-person…
STAT+: Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
As more emphasis is placed on the value of prescription medicines, a new study found…
STAT+: BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights
WASHINGTON — Everyone wants to know whether Michelle McMurry-Heath, the newly minted president of the…
STAT+: HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies
After a defeat in federal court, the Department of Health and Human Services withdrew an…
STAT+: A popular algorithm to predict sepsis misses most cases and sends frequent false alarms, study finds
It was a win win. Hospitals needed to prevent patient deaths from sepsis, a complication…
STAT+: Medical journal argues a drug maker’s libel suit is really a public relations campaign to chill research
File this under “Not every legal brief is eye-glazing.” Two months ago, Pacira Biosciences (PCRX)…
STAT+: European Union loses bid for faster deliveries of AstraZeneca Covid-19 vaccine
The European Union failed in its attempt to force AstraZeneca (AZN) to speed deliveries of…
STAT+: A California law that bans drug coupons failed to increase generic use
A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater…
STAT+: Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Poll: Many Americans concerned about FDA approval process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment…
STAT+: Athira Pharma CEO placed on leave amid allegations of altered images in her research papers
The chief executive of Athira Pharma, a biotech developing treatments for Alzheimer’s and other neurodegenerative…
STAT+: Billions spent on prescription drug ads may have increased Medicare spending
The large sums of money spent on advertising prescription drugs directly to consumers may have…
STAT+: Scientists unshelve a decades-old antibiotic to fight a new foe — ovarian cancer
Ovarian cancer, which kills about 15,000 Americans every year, has historically been one of the…
STAT+: Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare
Rise and shine, everyone, another busy day is on the way. Even so, there is…
STAT+: ‘A Lego kit for health care builders’: Jonathan Bush launches Zus with medical records in mind
Jonathan Bush is back for another act. On Thursday, the founder and former chief executive…
STAT+: Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge
The Open Society Foundations, one of the world’s largest backers of public health initiatives, is…
STAT+: American Medical Association delegates vote to support controversial Covid-19 IP waiver
The American Medical Association delegates voted at their annual meeting to support a controversial proposal…
STAT+: Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics
Good morning, folks. And how are you today? We are in fine spirits, thanks to…
STAT+: Lawmakers revive legislation to accelerate the development of new antibiotics
After months of anticipation, a bipartisan group of U.S. lawmakers is reintroducing bills in the…
STAT+: ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group…
STAT+: Former FDA chief Hahn defends his jump to Flagship Pioneering, the firm behind Moderna
When biotech investor Flagship Pioneering announced that it had hired former Food and Drug Administration…
.jpg)
STAT+: Amazon has made its Covid-19 test available online, alongside a diagnostics portal for consumers
Amazon has made its FDA-cleared Covid-19 test available to consumers online, alongside a consumer diagnostics…
STAT+: Centene to pay $143 million to two states to settle allegations of overcharging Medicaid
Centene (CNC), a major health insurer, agreed to pay a combined $143 million to Ohio…
STAT+: Biden administration moves to axe Trump 340B rule targeting community clinics
WASHINGTON — The Biden administration on Tuesday moved to axe a Trump-era policy that would…
STAT+: Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT+: Sage antidepressant achieves goals of large study, but questions about benefit linger
Sage Therapeutics said Tuesday that an experimental pill designed to alleviate depression with a two-week…
STAT+: Scientists CRISPR patients’ own immune cells in bid to shrink hard-to-treat GI tumors
Last year, researchers at the University of Pennsylvania, led by immunotherapy pioneer Carl June, showed…
STAT+: Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates
WASHINGTON — Sen. Chuck Grassley’s voice boomed through the Senate hearing room — it sounded…
STAT+: Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin
In a first-of-its-kind move, the Mississippi attorney general last week filed a lawsuit accusing several…
STAT+: Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos
Iteos Therapeutics said Monday that it has sold ownership rights to an experimental anti-TIGIT cancer…
STAT+: The unlikely force shaping Amazon’s health plans: A veteran, doctor, and TV persona with big ideas for tech
If you know the name Vin Gupta, chances are it’s because he tends to spar…
STAT+: ‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine
In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag…
STAT+: Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s
WASHINGTON — The Food and Drug Administration fast-tracked Biogen’s divisive Alzheimer’s drug Aduhelm, but it’s…
STAT+: A CRISPR treatment for blood diseases shows curative promise in small study
Twenty-two patients with inherited blood disorders were free of severe pain and the need for…
STAT+: Vertex shelves second drug for inherited lung disease, raising concerns about future growth
Vertex Pharmaceuticals said Thursday that an experimental protein “corrector” drug — the highest-priority medicine in…
STAT+: What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead
Despite all the excitement surrounding the FDA’s approval on Monday of a controversial treatment for Alzheimer’s disease, the…
STAT+: In potential big step forward for CAR-T, Bristol Myers says its therapy outperformed stem cell transplant in blood cancer
The treatment known as CAR-T, in which white blood cells are genetically modified to attack…
STAT+: Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots
Good morning and congrats if you caught the “ring of fire” some of us in…
STAT+: WTO members agree to step up talks about Covid-19 intellectual property proposals
In what is being described as a “major breakthrough,” a World Trade Organization council agreed…
STAT+: ‘Some very noble, some less than noble’: The growing health data marketplace sparks concern over patient privacy
The electronic health record has ushered in a golden era of precision medicine. It’s also…